retatrutide type 2 diabetes phase 2 trial 2024 π¨Breaking: Retatrutide's first 3 T2D data just dropped. βΈ A1C: β2.0% at 40 weeks βΈ Weight: β36.6 lbs (β16.8%) at 12 mg βΈ No weight loss plateau β curve still descending π A triple-action once-weekly injection
Description
Not an actual retatrutide product image.)
Amgen is testing a monthly injection that works differently and appears to help patients maintain their weight loss even after they stop taking it.
The program reflects the continued mainstreaming of weight-loss pharmacotherapy within retail and digital health settings.Through the platform, eligible adults aged 18 to 64 can schedule a $49 online video visit with a physician or nurse practitioner who evaluates their weight-loss goals and...
Industry grapples with changing consumer habits.
Refrigerated (2C 8C)
